These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 30549487)
41. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612 [TBL] [Abstract][Full Text] [Related]
42. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Joshi K; Pan X; Wang R; Yang E; Benson C Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694 [TBL] [Abstract][Full Text] [Related]
43. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689 [TBL] [Abstract][Full Text] [Related]
44. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Canuso CM; Bossie CA; Turkoz I; Alphs L Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322 [TBL] [Abstract][Full Text] [Related]
45. The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials. Mattila T; Koeter M; Wohlfarth T; Storosum J; van den Brink W; Derks E; Leufkens H; Denys D Eur Neuropsychopharmacol; 2017 Jan; 27(1):82-86. PubMed ID: 27842941 [TBL] [Abstract][Full Text] [Related]
46. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670 [TBL] [Abstract][Full Text] [Related]
47. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Patel R; Chesney E; Taylor M; Taylor D; McGuire P Psychol Med; 2018 Jul; 48(10):1616-1623. PubMed ID: 29039277 [TBL] [Abstract][Full Text] [Related]
48. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308 [TBL] [Abstract][Full Text] [Related]
49. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492 [TBL] [Abstract][Full Text] [Related]
50. A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Nakonezny PA; Lindow JC; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Byerly MJ Schizophr Res; 2020 Jun; 220():92-97. PubMed ID: 32269005 [TBL] [Abstract][Full Text] [Related]
51. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. Tempest M; Sapin C; Beillat M; Robinson P; Treur M J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007 [TBL] [Abstract][Full Text] [Related]
54. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Novakovic V; Adel T; Peselow E; Lindenmayer JP Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549 [TBL] [Abstract][Full Text] [Related]
55. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Vincent PD; Demers MF; Doyon-Kemp V; Duchesneau J; Halme A; Masson V Schizophr Res; 2017 Jul; 185():96-100. PubMed ID: 28119036 [TBL] [Abstract][Full Text] [Related]
56. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976 [TBL] [Abstract][Full Text] [Related]
57. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696 [TBL] [Abstract][Full Text] [Related]
58. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety. Morris MT; Tarpada SP Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271 [TBL] [Abstract][Full Text] [Related]
59. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Lindenmayer JP; Khan A Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275 [TBL] [Abstract][Full Text] [Related]
60. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]